Catalyst Pharmaceuticals Inc’s recently made public that its Director MCENANY PATRICK J acquired Company’s shares for reported $5.18 million on Jun 06 ’25. In the deal valued at $25.88 per share,200,000 shares were bought.
Then, O’Keeffe Charles B bought 8,222 shares, generating $205,550 in total proceeds.
Before that, O’Keeffe Charles B bought 41,778 shares. Catalyst Pharmaceuticals Inc shares valued at $1,044,973 were divested by the Former Director at a price of $25.01 per share.
Robert W. Baird initiated its Catalyst Pharmaceuticals Inc [CPRX] rating to an Outperform in a research note published on February 04, 2025; the price target was $28. A number of analysts have revised their coverage, including Stephens’s analysts, who began to cover the stock in mid November with a ‘”an Overweight”‘ rating. Citigroup began covering CPRX with “Buy” recommendation on March 14, 2024. BofA Securities started covering the stock on March 07, 2024. It rated CPRX as “a Buy”.
Price Performance Review of CPRX
On Monday, Catalyst Pharmaceuticals Inc [NASDAQ:CPRX] saw its stock fall -0.12% to $25.84. Over the last five days, the stock has gained 3.78%. Catalyst Pharmaceuticals Inc shares have risen nearly 23.81% since the year began. Nevertheless, the stocks have risen 58.43% over the past one year. While a 52-week high of $26.16 was reached on 06/09/25, a 52-week low of $14.75 was recorded on 01/08/25. SMA at 50 days reached $23.79, while 200 days put it at $22.16.
Levels Of Support And Resistance For CPRX Stock
The 24-hour chart illustrates a support level at 25.53, which if violated will result in even more drops to 25.21. On the upside, there is a resistance level at 26.37. A further resistance level may holdings at 26.89. The Relative Strength Index (RSI) on the 14-day chart is 66.41, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.78, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 26.24%. Stochastics %K at 85.10% indicates the stock is a selling.
The most recent change occurred on December 21, 2023 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $30 price target.
